Cargando…

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study

OBJECTIVE: Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ladouceur, Alexandra, Barnetche, Thomas, Mouterde, Gael, Tison, Alice, Bitoun, Samuel, Prey, Sorilla, Dutriaux, Caroline, Gerard, Emilie, Pham-Ledard, Anne, Beylot-Barry, Marie, Zysman, Maeva, Veillon, Rémi, Domblides, Charlotte, Daste, Amaury, Gross-Goupil, Marine, Sionneau, Baptiste, Lefort, Felix, Larroquette, Mathieu, Richez, Christophe, Truchetet, Marie-Elise, Schaeverbeke, Thierry, Kostine, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Inflammatory Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689372/ https://www.ncbi.nlm.nih.gov/pubmed/38030233 http://dx.doi.org/10.1136/rmdopen-2023-003795

Ejemplares similares

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study
por: Dousset, Léa, et al.
Publicado: (2021)

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
por: Bertrand, Anne, et al.
Publicado: (2015)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy
por: Kostine, Marie, et al.
Publicado: (2019)

Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as “toxic epidermal necrolysis-like”
por: Eldani, Céline, et al.
Publicado: (2023)

Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
por: Truchetet, Marie-Elise, et al.
Publicado: (2016)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study
por: Heraudet, Luc, et al.
Publicado: (2022)

Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases
por: Richez, Christophe, et al.
Publicado: (2020)

Implications du COVID-19 pour la prise en charge des rhumatismes inflammatoires chroniques()
por: Richez, Christophe, et al.
Publicado: (2020)

Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!
por: Luherne, Camille, et al.
Publicado: (2019)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
por: De La Fuente, Fanny, et al.
Publicado: (2022)

Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy
por: Vercruysse, François, et al.
Publicado: (2019)

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
por: Granet-Vaissiere, Estelle, et al.
Publicado: (2023)

Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study
por: Bazin, Thomas, et al.
Publicado: (2018)

Adaptation of multidisciplinary meeting decisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University Hospital
por: Heraudet, Luc, et al.
Publicado: (2020)

Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade
por: Larroquette, Mathieu, et al.
Publicado: (2022)

Locoregional Treatments for Digital Ulcers in Systemic Sclerosis: A Systematic Review
por: COSTEDOAT, Ingrid, et al.
Publicado: (2021)

Protective Microbiota: From Localized to Long-Reaching Co-Immunity
por: Chiu, Lynn, et al.
Publicado: (2017)

Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review
por: Gensous, Noémie, et al.
Publicado: (2017)

Long-lasting cutaneous tuberculosis owing to Mycobacterium bovis masquerading as sarcoidosis
por: Dequidt, Laure, et al.
Publicado: (2018)

La prophylaxie pré-exposition par tixagévimab/cilgavimab est efficace pour limiter le risque de contamination et la sévérité de la COVID-19 des patients atteints de maladies auto-immunes ou inflammatoires insuffisamment répondeurs à la vaccination
por: Thomas, M., et al.
Publicado: (2022)

Innate Immunity in Systemic Sclerosis Fibrosis: Recent Advances
por: Laurent, Paoline, et al.
Publicado: (2018)

Relevance of circulating Semaphorin 4A for rheumatoid arthritis response to treatment
por: Avouac, Jérôme, et al.
Publicado: (2023)

Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort
por: Truchetet, Marie-Elise, et al.
Publicado: (2022)

Congenital haemangiomas: a single-centre retrospective review
por: Braun, Victoire, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Diagnostic value of ultrasound in calcium pyrophosphate deposition disease: a systematic review and meta-analysis
por: Gamon, Etienne, et al.
Publicado: (2015)

Bell's palsy during rechallenge of immune checkpoint inhibitor
por: Takemura, Kohji, et al.
Publicado: (2023)

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge
por: Park, Benjamin C, et al.
Publicado: (2022)

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
por: Allouchery, Marion, et al.
Publicado: (2020)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity
por: Poglio, Sandrine, et al.
Publicado: (2020)

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling
por: Gros, Audrey, et al.
Publicado: (2022)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
por: Perdyan, Adrian, et al.
Publicado: (2023)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
por: Isik, Busra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1ksa1gnkch3nsk8q1ngrt1d98r